Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Accumulated Expenses: 2014-2025

Historic Accumulated Expenses for ImmunityBio (IBRX) over the last 10 years, with Sep 2025 value amounting to $43.6 million.

  • ImmunityBio's Accumulated Expenses rose 0.01% to $43.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $43.6 million, marking a year-over-year increase of 0.01%. This contributed to the annual value of $40.6 million for FY2024, which is 4.98% down from last year.
  • As of Q3 2025, ImmunityBio's Accumulated Expenses stood at $43.6 million, which was up 22.12% from $35.7 million recorded in Q2 2025.
  • Over the past 5 years, ImmunityBio's Accumulated Expenses peaked at $64.9 million during Q3 2023, and registered a low of $27.9 million during Q1 2025.
  • For the 3-year period, ImmunityBio's Accumulated Expenses averaged around $44.0 million, with its median value being $42.7 million (2023).
  • Per our database at Business Quant, ImmunityBio's Accumulated Expenses spiked by 600.73% in 2021 and then slumped by 43.30% in 2024.
  • Over the past 5 years, ImmunityBio's Accumulated Expenses (Quarterly) stood at $51.4 million in 2021, then declined by 18.61% to $41.8 million in 2022, then climbed by 2.11% to $42.7 million in 2023, then declined by 4.98% to $40.6 million in 2024, then increased by 0.01% to $43.6 million in 2025.
  • Its last three reported values are $43.6 million in Q3 2025, $35.7 million for Q2 2025, and $27.9 million during Q1 2025.